ProQR (PRQR) CSO details sizeable option grants and share stake
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
ProQR Therapeutics N.V. director and Chief Scientific Officer Gerardus Johannes Platenburg has filed an initial statement of beneficial ownership. The filing lists direct holdings of 824,388 Ordinary Shares.
It also details multiple option grants to buy Ordinary Shares at exercise prices ranging from $0.6700 to $15.7800, with expiration dates between 2026-12-31 and 2035-12-31. Footnotes explain that some options are fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to his continuous service.
The transaction summary shows holding entries only, with no reported purchases, sales, exercises, gifts, or tax-withholding dispositions in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Platenburg Gerardus Johannes
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 61,453 shares (Direct);
Ordinary Shares — 824,388 shares (Direct)
Footnotes (1)
- Fully vested. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
FAQ
What does ProQR (PRQR) Chief Scientific Officer Platenburg report in this Form 3?
He reports his initial beneficial ownership in ProQR, including direct Ordinary Share holdings and a series of share options. The filing is a baseline disclosure of his equity position, not a record of new purchases or sales.
How do Platenburg’s ProQR (PRQR) options vest according to the Form 3 footnotes?
Footnotes state certain options are fully vested, while others vest 25% on January 1 of 2024, 2025, 2026, or 2027. The remaining 75% vests in 12 substantially equal quarterly installments, contingent on his continuous service.
Does this ProQR (PRQR) Form 3 show any insider buying or selling by Platenburg?
No, it does not show insider buying or selling. The transaction records are classified as holdings, and the transaction summary indicates zero buys, zero sells, and no option exercises, gifts, or tax-withholding dispositions in this disclosure.
What does the derivative summary reveal about Platenburg’s ProQR (PRQR) option position?
The derivative summary lists unexercised “Share Option (Right to Buy)” positions over specified numbers of Ordinary Shares, with defined exercise prices and expiration dates. It reflects option awards he continues to hold rather than recent exercises or sales.